 |
 Video: What is a Stock Split?
|
|
|
| Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co. also has product candidates in preclinical and clinical development designed to utilize its bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease. According to our Ocular Therapeutix stock split history records, Ocular Therapeutix has had 0 splits. | |
|
Ocular Therapeutix (OCUL) has 0 splits in our Ocular Therapeutix stock split history database.
Looking at the Ocular Therapeutix stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ocular Therapeutix shares, starting with a $10,000 purchase of OCUL, presented on a split-history-adjusted basis factoring in the complete Ocular Therapeutix stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/28/2014 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$12.84 |
|
| End price/share: |
$7.58 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-40.97% |
|
| Average Annual Total Return: |
-5.27% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$5,905.45 |
|
| Years: |
9.73 |
|
|
|
|
|
